Key result
Beta-blockers are questioned by emerging evidence as a preferred rate-control therapy in patients with atrial fibrillation.
Emerging evidence challenges the current strong recommendation for beta-blockers as the preferred rate-control therapy in patients with atrial fibrillation.
Atrial fibrillation is closely associated with heart failure and adversely affects outcomes. Beta-blockers are strongly recommended to avoid rapid ventricular conduction and tachycardia-induced cardiomyopathy. In this Viewpoint article, we discuss an emerging body of evidence that questions beta-blockers as a preferred rate-control therapy in patients with atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Meyer et al. (2023) studied this question. Beta-blockers are questioned by emerging evidence as a preferred rate-control therapy in patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: